RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Hypercholesterolemia is correlated with an increased risk of idiopathic sudden sensorineural hearing loss: a historical prospective cohort study.

Ear and Hearing 2014 March
OBJECTIVE: Despite the many studies on the associated risk of cardiovascular and cerebrovascular events in patients with hypercholesterolemia (HCh), an association between HCh and the development of idiopathic sudden sensorineural hearing loss (ISSNHL) has been examined in only a few case-control studies. We tested the hypothesis that HCh is a risk factor for developing ISSNHL.

DESIGN: Using the Taiwan Longitudinal Health Insurance Database, we conducted a historical prospective cohort study to compare patients diagnosed with HCh from January 1, 2001, through to December 31, 2006 (N = 73,957) with age-matched controls (N = 73,957). We followed each patient until the end of 2009 and evaluated the incidence of ISSNHL for a minimum of 3 years after the initial HCh diagnosis.

RESULTS: The incidence of ISSNHL was 1.62 times higher in the HCh cohort than in the non-HCh cohort (10.67 versus 6.61 per 10,000 person-years). Using Cox proportional hazard regressions, the adjusted hazard ratio was 1.60 (95% confidence interval [CI] = 1.39-1.85). An increased risk of developing ISSNHL, with adjusted hazard ratios of 1.48 (95% CI = 1.08-2.04) and 1.69 (95% CI = 1.18-2.43), was observed in HCh patients with newly diagnosed comorbidities of stroke or stroke combined with coronary artery diseases, which are both expected to reflect the severity of HCh.

CONCLUSIONS: A diagnosis of HCh may indicate an independent risk for ISSNHL. This finding suggests that an underlying vascular mechanism contributes to the development of ISSNHL. We suggest that physicians counsel patients with HCh to seek medical attention if they have hearing impairments, because they may also have an increased risk of developing ISSNHL.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app